CJC-1295 (No DAC)

CJC-1295 (No DAC)

CJC-1295 (No DAC) is a synthetic 30-amino acid peptide that serves as a selective agonist for Growth Hormone-Releasing Hormone (GHRH) receptors. Its primary mechanism of action involves the stimulation of pituitary somatotrophs to induce the secretion of growth hormone (GH) and the subsequent production of Insulin-like Growth Factor 1 (IGF-1).

The absence of a Drug Affinity Complex (DAC) ensures that this analog has a short plasma half-life. This characteristic allows researchers to observe the effects of transient growth hormone spikes, which are more aligned with natural biological rhythms compared to the continuous elevation provided by long-acting analogs.

CJC-1295 (No DAC) Overview

CJC-1295 (No DAC), commonly referred to as Modified GRF 1-29, is derived from the biologically active fragment of GHRH. To enhance its stability, the sequence includes four amino acid substitutions (at positions 2, 8, 15, and 27) that prevent rapid enzymatic degradation while maintaining high receptor affinity. These modifications allow for a longer duration of action than native GHRH while still preserving a pulsatile release pattern.

In many experimental settings, CJC-1295 (No DAC) is studied in conjunction with GHRP-type secretagogues like Ipamorelin. This combination is explored for its ability to synergistically increase the amplitude and frequency of GH pulses. Such research is critical for understanding the complex feedback loops that govern energy metabolism, tissue repair, and hormonal homeostasis.

CJC-1295 (No DAC) Structure

The structural configuration of CJC-1295 (No DAC) is defined by its ability to resist protease activity while effectively mimicking the native GHRH molecule.

Molecular Structure Formula:

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

Comparative Specification Table

Property

Specification Details

Sequence Length

30 Amino Acids

Modification

No DAC (Drug Affinity Complex)

Physical Form

Lyophilized White Crystalline Powder

Target Receptor

GHRH Receptor (Pituitary)

Molecular Mass

3367.9

CJC-1295 (No DAC) Research

Endocrine Axis Modulation

CJC-1295 (No DAC) is used extensively in research regarding the Hypothalamic-Pituitary-Somatotropic axis. By providing a discrete stimulatory signal, it allows investigators to model the natural secretory rhythms of growth hormone. This is particularly useful in studying the inhibition of somatostatin and the regulatory role of IGF-1 in maintaining hormonal balance.

Metabolism and Nutrient Partitioning

The GH pulses induced by this peptide are central to studies of metabolic efficiency. Research areas include:

• Lipolysis: The process by which the body breaks down fats for energy.
• Glucose Management: Investigating the interactions between GH secretion and insulin sensitivity.
• Anabolic Signaling: Evaluating the pathways responsible for protein synthesis and nitrogen retention in muscle tissue.

Tissue Repair and Musculoskeletal Health

The regenerative properties of CJC-1295 (No DAC) are studied in the context of wound healing and connective tissue remodeling. By elevating IGF-1, the peptide supports the synthesis of collagen and the proliferation of fibroblasts. These effects are investigated for their potential to enhance the recovery of tendons, ligaments, and skin following injury.

Summary and Research Use Notice

CJC-1295 (No DAC) is a vital tool for the scientific study of endocrine dynamics and regenerative medicine. Its ability to provide transient, controlled GH stimulation makes it a preferred choice for high-precision laboratory experiments.

This product is supplied for laboratory and scientific research purposes only. It is not intended for human consumption or veterinary administration.

Article Author

This literature review was compiled, edited, and organized by Dr. Cyrill Y. Bowers, Ph.D. Dr. Bowers is a highly regarded endocrinologist and peptide biochemist recognized for his groundbreaking discovery and characterization of growth hormone-releasing peptides (GHRPs). His pioneering investigations clarified how GHRH analogs and GHRPs work together to enhance pituitary growth hormone secretion, establishing the scientific basis for modern GH secretagogue and analog research. Through decades of work in peptide pharmacology, Dr. Bowers has made lasting contributions to the understanding of hypothalamic-pituitary regulation and the therapeutic potential of GH-axis modulation.

Scientific Journal Author

Dr. Cyrill Y. Bowers has devoted much of his career to studying growth hormone-releasing factors, their receptor interactions, and their cooperative effects with GHRH analogues. His collaborative research with prominent endocrinologists such as L.A. Frohman, C.J. Strasburger, and E.E. Muller has been instrumental in advancing knowledge of GH/IGF-1 physiology, pulsatile hormone dynamics, and endocrine feedback mechanisms. Among his most influential works is the publication "Discovery of Growth Hormone-Releasing Peptides" (Endocrine Reviews, 1998; 19(6):801-822), which remains a cornerstone reference in GH secretagogue science. This acknowledgment serves solely to recognize the scientific achievements of Dr. Bowers and his collaborators.

Storage Instructions

Lyophilization and Room Temperature Stability

The freeze-drying process, or lyophilization, creates a stable crystalline structure that protects the peptide from environmental degradation. During transit, lyophilized CJC-1295 (No DAC) can remain stable for up to 4 months at room temperature. For long-term preservation, it should be kept in a freezer at -80 degrees Celsius to ensure it retains its structural integrity over several years.

Handling and Reconstitution

When preparing for research, allow the vial to reach room temperature before introducing bacteriostatic water. This prevents condensation from forming on the peptide. Once reconstituted, the solution should be handled with care; do not shake the vial vigorously. The solution must be refrigerated at all times and used within a 30-day window to prevent bacterial growth and peptide breakdown.

Contamination Prevention

Ensure all storage containers are chemically inert and appropriately sized to minimize air space. Protect the peptide from light exposure at all times, as UV rays can lead to the oxidation of certain amino acid residues. Dividing the peptide into smaller aliquots for individual experiments can help prevent repeated temperature fluctuations.